Market Research Logo

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2015’, provides an overview of the Female Hypoactive Sexual Desire Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Female Hypoactive Sexual Desire Disorder Overview
Therapeutics Development
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis
Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies
Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Female Hypoactive Sexual Desire Disorder - Products under Development by Companies
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
Apricus Biosciences, Inc.
Emotional Brain BV
Palatin Technologies, Inc.
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(bupropion hydrochloride + trazodone hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
flibanserin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates
Female Hypoactive Sexual Desire Disorder - Dormant Projects
Female Hypoactive Sexual Desire Disorder - Dormant Projects
Female Hypoactive Sexual Desire Disorder - Product Development Milestones
Featured News & Press Releases
Jun 05, 2015: S1 Biopharma Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
Jun 04, 2015: Palatin Supports FDA Advisory Committee's Recommendation to Approve the First-Ever Treatment for Hypoactive Sexual Desire Disorder
Jun 02, 2015: FDA Advisory Committee to Review Sprout Pharma’s HSDD Drug
Mar 04, 2015: UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets
Feb 17, 2015: Sprout Pharmaceuticals Resubmits Flibanserin New Drug Application For The Treatment Of Hypoactive Sexual Desire Disorder In Premenopausal Women
Jan 07, 2015: Sprout Pharmaceuticals To Present At 33rd Annual J.P. Morgan Healthcare Conference
Nov 22, 2014: Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment
Nov 22, 2014: Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released At Sexual Medicine Society of North America Meeting
Feb 11, 2014: Sprout Pharmaceuticals Receives Clear Guidance From FDA On Path Forward To Resubmit New Drug Application For Flibanserin, The First Potential Medical Treatment For Hypoactive Sexual Desire Disorder In Premenopausal Women
Dec 11, 2013: Sprout Pharmaceuticals Appeals FDA Decision On New Drug Application For Flibanserin To Treat Hypoactive Sexual Desire Disorder In Premenopausal Women
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2015
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Products under Development by Companies, H2 2015
Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H2 2015
Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H2 2015
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H2 2015
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H2 2015
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report